{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:58:14Z","timestamp":1791421094318,"version":"4.3.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,9,17]],"date-time":"2011-09-17T00:00:00Z","timestamp":1316217600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00259-011-1935-5","type":"journal-article","created":{"date-parts":[[2011,9,16]],"date-time":"2011-09-16T19:42:08Z","timestamp":1316202128000},"page":"72-82","source":"Crossref","is-referenced-by-count":71,"title":["Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET\/CT for staging enteropancreatic neuroendocrine tumours"],"prefix":"10.1007","volume":"39","author":[{"given":"Nils F.","family":"Schreiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munenobu","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Buchert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Huppertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich-Frank","family":"Pape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,17]]},"reference":[{"issue":"4","key":"1935_CR1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","volume":"97","author":"IM Modlin","year":"2003","unstructured":"Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97(4):934\u201359.","journal-title":"Cancer"},{"issue":"2","key":"1935_CR2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000182196","volume":"90","author":"G Kl\u00f6ppel","year":"2009","unstructured":"Kl\u00f6ppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 2009;90(2):162\u20136.","journal-title":"Neuroendocrinology"},{"issue":"3","key":"1935_CR3","first-page":"225","volume":"49","author":"PF Rambaldi","year":"2005","unstructured":"Rambaldi PF, Cuccurullo V, Briganti V, Mansi L. The present and future role of (111)In pentetreotide in the PET era. Q J Nucl Med Mol Imaging 2005;49(3):225\u201335.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"8","key":"1935_CR4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","volume":"20","author":"EP Krenning","year":"1993","unstructured":"Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20(8):716\u201331.","journal-title":"Eur J Nucl Med"},{"issue":"7","key":"1935_CR5","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00259-010-1473-6","volume":"37","author":"E Bombardieri","year":"2010","unstructured":"Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37(7):1441\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1935_CR6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1536-1632(03)00038-6","volume":"5","author":"J Kowalski","year":"2003","unstructured":"Kowalski J, Henze M, Schuhmacher J, M\u00e4cke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5(1):42\u20138.","journal-title":"Mol Imaging Biol"},{"issue":"10","key":"1935_CR7","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00259-007-0450-1","volume":"34","author":"I Buchmann","year":"2007","unstructured":"Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Sch\u00e4fer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34(10):1617\u201326.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1935_CR8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3413\/nukmed-0214","volume":"48","author":"H Hartmann","year":"2009","unstructured":"Hartmann H, Z\u00f6phel K, Freudenberg R, Oehme L, Andreeff M, Wunderlich G, et al. Radiation exposure of patients during 68Ga-DOTATOC PET\/CT examinations. Nuklearmedizin 2009;48(5):201\u20137.","journal-title":"Nuklearmedizin"},{"issue":"5","key":"1935_CR9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00117-002-0717-2","volume":"42","author":"P Gocke","year":"2002","unstructured":"Gocke P, Debatin JF, D\u00fcrselen LF. Process management and controlling in diagnostic radiology in the hospital. Radiologe 2002;42(5):332\u201343.","journal-title":"Radiologe"},{"issue":"7","key":"1935_CR10","first-page":"1134","volume":"42","author":"HR Balon","year":"2001","unstructured":"Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, et al. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med 2001;42(7):1134\u20138.","journal-title":"J Nucl Med"},{"issue":"10","key":"1935_CR11","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2967\/jnumed.107.040378","volume":"48","author":"KP Zhernosekov","year":"2007","unstructured":"Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007;48(10):1741\u20138.","journal-title":"J Nucl Med"},{"issue":"18","key":"1935_CR12","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26(18):3063\u201372.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1935_CR13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3747\/co.v17i3.484","volume":"17","author":"W Kocha","year":"2010","unstructured":"Kocha W, Maroun J, Kennecke H, Law C, Metrakos P, Ouellet JF, et al. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol 2010;17(3):49\u201364.","journal-title":"Curr Oncol"},{"issue":"6","key":"1935_CR14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3109\/0284186X.2010.492791","volume":"49","author":"ET Janson","year":"2010","unstructured":"Janson ET, S\u00f8rbye H, Welin S, Federspiel B, Gr\u00f8nbaek H, Hellman P, et al. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol 2010;49(6):740\u201356.","journal-title":"Acta Oncol"},{"issue":"2","key":"1935_CR15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000225952","volume":"90","author":"R Arnold","year":"2009","unstructured":"Arnold R, Chen YJ, Costa F, Falconi M, Gross D, Grossman AB, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009;90(2):227\u201333.","journal-title":"Neuroendocrinology"},{"issue":"2","key":"1935_CR16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000184855","volume":"90","author":"A Sundin","year":"2009","unstructured":"Sundin A, Vullierme MP, Kaltsas G, Pl\u00f6ckinger U, Mallorca Consensus Conference participants, European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009;90(2):167\u201383.","journal-title":"Neuroendocrinology"},{"issue":"4","key":"1935_CR17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s00117-007-1547-z","volume":"48","author":"C Plathow","year":"2008","unstructured":"Plathow C, Walz M, Lichy MP, Aschoff P, Pfannenberg C, Bock H, et al. Cost considerations for whole-body MRI and PET\/CT as part of oncologic staging. Radiologe 2008;48(4):384\u201396.","journal-title":"Radiologe"},{"issue":"6","key":"1935_CR18","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1007\/s00330-006-0183-8","volume":"16","author":"GP Schmidt","year":"2006","unstructured":"Schmidt GP, Haug AR, Schoenberg SO, Reiser MF. Whole-body MRI and PET-CT in the management of cancer patients. Eur Radiol 2006;16(6):1216\u201325.","journal-title":"Eur Radiol"},{"key":"1935_CR19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-0029-1215599","volume":"32","author":"RP Baum","year":"2009","unstructured":"Baum RP, Prasad V, H\u00f6rsch D. Molekulare Bildgebung neuroendokriner Tumoren mit 68Ga-markierten Peptiden (Somatostatinrezeptor-PET\/CT). Nuklearmediziner 2009;32:115\u201330.","journal-title":"Nuklearmediziner"},{"issue":"8632","key":"1935_CR20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(89)91258-0","volume":"1","author":"EP Krenning","year":"1989","unstructured":"Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989;1(8632):242\u20134.","journal-title":"Lancet"},{"issue":"5","key":"1935_CR21","first-page":"652","volume":"33","author":"EP Krenning","year":"1992","unstructured":"Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992;33(5):652\u20138.","journal-title":"J Nucl Med"},{"issue":"2","key":"1935_CR22","first-page":"317","volume":"35","author":"PM Smith-Jones","year":"1994","unstructured":"Smith-Jones PM, Stolz B, Bruns C, Albert R, Reist HW, Fridrich R, et al. Gallium-67\/gallium-68-[DFO]-octreotide\u2013a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 1994;35(2):317\u201325.","journal-title":"J Nucl Med"},{"issue":"4","key":"1935_CR23","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s002590050064","volume":"24","author":"M Jong de","year":"1997","unstructured":"de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24(4):368\u201371.","journal-title":"Eur J Nucl Med"},{"issue":"9100","key":"1935_CR24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(05)78355-0","volume":"351","author":"A Otte","year":"1998","unstructured":"Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351(9100):417\u20138.","journal-title":"Lancet"},{"issue":"7","key":"1935_CR25","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s00259-006-0317-x","volume":"34","author":"P Antunes","year":"2007","unstructured":"Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34(7):982\u201393.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1935_CR26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000265561","volume":"91","author":"J Ruf","year":"2010","unstructured":"Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A, et al. Impact of multiphase 68Ga-DOTATOC-PET\/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 2010;91(1):101\u20139.","journal-title":"Neuroendocrinology"},{"issue":"4","key":"1935_CR27","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","volume":"48","author":"M Gabriel","year":"2007","unstructured":"Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48(4):508\u201318.","journal-title":"J Nucl Med"},{"issue":"3","key":"1935_CR28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11307-010-0374-1","volume":"13","author":"Y Krausz","year":"2011","unstructured":"Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, et al. (68)Ga-DOTA-NOC PET\/CT imaging of neuroendocrine tumors: comparison with (111)In-DTPA-octreotide (OctreoScan\u00ae). Mol Imaging Biol 2011;13(3):583\u201393.","journal-title":"Mol Imaging Biol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-011-1935-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-011-1935-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-011-1935-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T19:57:23Z","timestamp":1560628643000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-011-1935-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,17]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1935"],"URL":"https:\/\/doi.org\/10.1007\/s00259-011-1935-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,17]]}}}